We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

3 hedge funds and large institutions have $4.95K invested in NeuBase Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% less funds holding

Funds holding: 19 → 3 (-16)

94% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 17

97% less capital invested

Capital invested by funds: $177K → $4.95K (-$172K)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
-16
Holders Change %
-84.21%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBA
Baader Bank Aktiengesellschaft
Germany
+$6.7K

Top Sellers

Rank Fund Capital Flow
1
DCM
DME Capital Management
New York
-$61.3K
2
Renaissance Technologies
Renaissance Technologies
New York
-$40K
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$28.1K
4
CMU
Carnegie Mellon University
Pennsylvania
-$21.1K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$8.54K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baader Bank Aktiengesellschaft
Germany
$4.95K +$6.7K +16,089 New
DCM
2
DME Capital Management
New York
– -$61.3K -136,350 Closed
Renaissance Technologies
3
Renaissance Technologies
New York
– -$40K -88,229 Closed
Point72 Asset Management
4
Point72 Asset Management
Connecticut
– -$28.1K -62,500 Closed
CMU
5
Carnegie Mellon University
Pennsylvania
– -$21.1K -46,970 Closed
Vanguard Group
6
Vanguard Group
Pennsylvania
– -$8.54K -18,981 Closed
PCM
7
Prelude Capital Management
New York
– -$7K -15,550 Closed
Geode Capital Management
8
Geode Capital Management
Massachusetts
– -$6.84K -15,482 Closed
UBS Group
9
UBS Group
Switzerland
– -$1.82K -4,056 Closed
TRCT
10
Tower Research Capital (TRC)
New York
– -$1.16K -2,572 Closed
CSS
11
Cubist Systematic Strategies
Connecticut
– -$563 -1,251 Closed
Bank of America
12
Bank of America
North Carolina
– -$361 -804 Closed
First Manhattan
13
First Manhattan
New York
– -$158 -353 Closed
Wells Fargo
14
Wells Fargo
California
– -$35 -79 Closed
Osaic Holdings
15
Osaic Holdings
Arizona
– -$9 -21 -95%
PNC Financial Services Group
16
PNC Financial Services Group
Pennsylvania
– -$9 -21 Closed
NFSG
17
Newbridge Financial Services Group
Florida
– -$5 -12 Closed
Morgan Stanley
18
Morgan Stanley
New York
– -$4 -9 Closed

NBSE Hedge Fund Activity: Q2 2024 in Review

3 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2024, worth a combined $4.95K — down 97% from $177K a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of NBSE and 1 opened new positions — a net loss of 16 holders — while 1 trimmed existing stakes and 0 added.

The largest buyer was Baader Bank Aktiengesellschaft, opening a new position worth an estimated $6.7K. The largest seller was DME Capital Management, exiting entirely with an estimated $61.3K sold.

  • 3 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2024, down from 19 in Q1 2024.
  • Funds reported $4.95K of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2024, down 97% quarter-over-quarter.
  • 1 fund opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2024 and 17 closed out, a net change of -16 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2024 was Baader Bank Aktiengesellschaft, an estimated $6.7K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2024 was DME Capital Management, an estimated $61.3K sold.

Based on aggregated 13F filings for Q2 2024.